Unlike the already-marketed CDK4/6 anti-tumor inhibitors, BEBT-209 improves the selectivity of CDK4 over CDK6, which is expected to reduce the hematological and immunosuppressive toxicity caused by CDK6 activity inhibition [119]. This evidence concerns the gene CDK6 and neoplasm.